Denosumab Effective for Giant-Cell Tumor of Bone

According to a recent phase 2 study, denosumab is an effective treatment for patients with giant-cell tumor of bone (GCTB).In this study, results of which are published in The Lancet Oncology, 532 adult and skeletally mature adolescent patients with histologically confirmed and radiographically measurable GCTB were enrolled. In order to be eligible, participants had to be at or above the age of 12 years, weigh at least 45 kg, have a Karnofsky performance status of 50% or higher (Eastern Cooperat...
Continue reading

Durvalumab Plus Platinum/Etoposide for Extensive-Stage SCLC: Luis Paz-Ares, MD

Because most patients with small-cell lung cancer (SCLC) present with extensive-stage disease—in which the cancer has spread to both lungs or throughout the body—survival rates are poor, and there is a need to develop alternative treatments to improve outcomes. In their study now published in The Lancet, Luis Paz-Ares, MD, and colleagues found that in patients with extensive-stage SCLC (ES-SCLC), the addition of the immunotherapy drug durvalumab to a chemotherapy regimen of platinum/etoposide si...
Continue reading

Why Do Pre-Immunotherapy Antibiotics Reduce Survival? With David J. Pinato, MD, MRes, PhD

​Many patients with cancer experience infections requiring treatment. However, David Pinato, MD, MRes, PhD, and colleagues recently found that in patients with non-small cell lung cancer (NSCLC), melanoma, and other tumor types, broad-spectrum antibiotic treatment administered within 30 days prior to the commencement of immune checkpoint inhibitor therapy dramatically worsened overall survival (2 vs 26 months) and increased the risk of treatment-refractory disease. In this interview with i3 Heal...
Continue reading

Immuno-Oncology and Checkpoint Inhibition in Cervical Cancer: Bradley Monk, MD, FACS, and Ramez Eskander, MD

​Unlike that of other gynecological malignancies, the etiology of cervical cancer is the human papillomavirus (HPV). This fact plays a role in how cervical cancer is perceived as immunogenic: T cells themselves are involved in the immune response and in the control of viral infections and the development of these tumors. In this discussion with i3 Health, Bradley Monk, MD, FACS, FACOG, Professor of Gynecologic Oncology at the University of Arizona and Creighton University, and Ramez Eskander, MD...
Continue reading

Nanovaccines: A New Approach for Melanoma Treatment

Researchers have developed a nanovaccine that, when combined with antibodies and ibrutinib, shows potential as an effective treatment for melanoma.Immune checkpoint therapy, a form of cancer therapy which targets the immune system, has proven to be an effective treatment method for melanoma, the most aggressive type of skin cancer. However, immune checkpoint therapy is limited by a low response rate, severe side effects, and acquired resistance to treatment. There is a need to develop an alterna...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.